About INNOCARE Company

InnoCare, Inc. of Nuocheng Jianhua Pharmaceutical Co., Ltd. was founded by a group of enterprising scientists focused on providing patients around the world with modern, innovative medicines to fight cancer and autoimmune diseases. Nuocheng Jianhua is an innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D and commercialization capabilities, focuses on fields where there is huge unmet clinical demand, such as tumors and autoimmune diseases, and develops best-in-class or first-of-its-kind drugs with breakthrough potential in the global market. Obutinib uses a monocyclic parent nucleus design. Its molecular structure has fewer hydrogen bond sites and no chiral center, which reduces the spatial conformation of Michael's receptors, thereby effectively improving selectivity and inhibition of BTK kinase. The company's shares were listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on September 21, 2022.